Ra Capital Management, L.P. Buys 31,000 Shares of Artiva Biotherapeutics (NASDAQ:ARTV) Stock

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Director Ra Capital Management, L.P. acquired 31,000 shares of the business’s stock in a transaction dated Thursday, June 25th. The stock was purchased at an average price of $8.88 per share, with a total value of $275,280.00. Following the completion of the acquisition, the director directly owned 16,794,043 shares in the company, valued at approximately $149,131,101.84. This represents a 0.18% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Friday, June 26th, Ra Capital Management, L.P. acquired 1,876 shares of Artiva Biotherapeutics stock. The shares were purchased at an average cost of $8.98 per share, for a total transaction of $16,846.48.
• On Tuesday, June 16th, Ra Capital Management, L.P. bought 124,893 shares of Artiva Biotherapeutics stock. The stock was purchased at an average price of $8.89 per share, with a total value of $1,110,298.77.
• On Monday, June 15th, Ra Capital Management, L.P. bought 15,414 shares of Artiva Biotherapeutics stock. The stock was purchased at an average cost of $8.99 per share, with a total value of $138,571.86.
• On Friday, June 12th, Ra Capital Management, L.P. bought 391,019 shares of Artiva Biotherapeutics stock. The stock was purchased at an average cost of $8.57 per share, with a total value of $3,351,032.83.
• On Thursday, June 11th, Ra Capital Management, L.P. purchased 548,580 shares of Artiva Biotherapeutics stock. The shares were acquired at an average price of $7.91 per share, for a total transaction of $4,339,267.80.
• On Wednesday, June 10th, Ra Capital Management, L.P. purchased 103 shares of Artiva Biotherapeutics stock. The shares were acquired at an average cost of $7.00 per share, for a total transaction of $721.00.
• On Tuesday, June 9th, Ra Capital Management, L.P. purchased 479,039 shares of Artiva Biotherapeutics stock. The shares were acquired at an average cost of $6.91 per share, for a total transaction of $3,310,159.49.
• On Monday, May 11th, Ra Capital Management, L.P. acquired 6,510,416 shares of Artiva Biotherapeutics stock. The stock was acquired at an average price of $11.52 per share, with a total value of $74,999,992.32.

Artiva Biotherapeutics Stock Down 0.4%

Shares of Artiva Biotherapeutics stock traded down $0.04 during trading on Monday, reaching $9.58. The company’s stock had a trading volume of 446,432 shares, compared to its average volume of 382,661. Artiva Biotherapeutics, Inc. has a 52-week low of $1.48 and a 52-week high of $14.53. The firm’s 50-day moving average is $9.40 and its two-hundred day moving average is $6.58. The company has a market cap of $236.79 million, a price-to-earnings ratio of -2.71 and a beta of 2.40.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its earnings results on Friday, May 8th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). On average, equities research analysts anticipate that Artiva Biotherapeutics, Inc. will post -2.45 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Needham & Company LLC reiterated a “buy” rating and issued a $41.00 price objective on shares of Artiva Biotherapeutics in a report on Monday, June 8th. HC Wainwright raised their price target on Artiva Biotherapeutics from $15.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Friday, April 24th. Wedbush boosted their price objective on Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an “outperform” rating in a research report on Monday, May 11th. Finally, Wall Street Zen lowered Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, May 17th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $39.00.

Hedge Funds Weigh In On Artiva Biotherapeutics

A number of hedge funds have recently modified their holdings of ARTV. Bank of America Corp DE raised its stake in shares of Artiva Biotherapeutics by 225.8% during the third quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock valued at $46,000 after acquiring an additional 11,190 shares during the last quarter. Prelude Capital Management LLC bought a new stake in shares of Artiva Biotherapeutics in the third quarter worth about $41,000. Dimensional Fund Advisors LP bought a new stake in shares of Artiva Biotherapeutics in the first quarter worth about $131,000. OMERS ADMINISTRATION Corp purchased a new position in Artiva Biotherapeutics during the 4th quarter valued at about $91,000. Finally, Sanctuary Advisors LLC purchased a new position in Artiva Biotherapeutics during the 1st quarter valued at about $139,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.